trending Market Intelligence /marketintelligence/en/news-insights/trending/AEGkYGbDudHLvgw2jYnHAw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Medtronic device cuts infection risk in patients with heart implants in study

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Medtronic device cuts infection risk in patients with heart implants in study

Medtronic PLC said its TYRX absorbable antibacterial envelope cut the risk of infections in patients with electronic heart implants in a trial.

Under the Wrap-It trial, the TYRX envelope reduced the risk of major infection by 40% in patients with cardiac implantable electronic devices, or CIEDs, compared to those treated with standard-of-care antibiotics given before surgery — the trial's main goal. The envelope also reduced risk of pocket infection by 61% compared to pre-operative antibiotics.

The 6,983-patient study's results were presented March 17 in the American College of Cardiology's 68th Annual Scientific Sessions.

CIEDs, such as cardiac pacemakers and implantable cardioverter defibrillators, are used to correct abnormal heart rhythms. The devices are linked to a rising rate of infections, the treatment of which can be expensive for patients.

The Dublin-based company's TYRX envelope works by encasing and stabilizing the CIEDs in a mesh that contains antibiotics minocycline and rifampin. The envelope is absorbed by the patient's body about nine weeks after it is implanted.

The TYRX envelope was approved in the U.S. and EU in 2013 and 2014, respectively.